Cargando…

The clinical efficacy of lefamulin in the treatment of elderly patients with community-acquired bacterial pneumonia

Detalles Bibliográficos
Autores principales:	Tang, Hung-Jen, Lai, Chih-Cheng, Chao, Chien-Ming
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AME Publishing Company 2020
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7475535/ https://www.ncbi.nlm.nih.gov/pubmed/32944382 http://dx.doi.org/10.21037/jtd-19-3805

Ejemplares similares

Lefamulin vs moxifloxacin for community-acquired bacterial pneumonia
por: Tang, Hung-Jen, et al.
Publicado: (2020)

Lefamulin: a New Hope in the Field of Community-Acquired Bacterial Pneumonia
por: Adhikary, Shubham, et al.
Publicado: (2022)

Lefamulin, a recently approved novel antibacterial agent to fight against community-acquired bacterial pneumonia
por: Choudhury, Shouvik, et al.
Publicado: (2021)

Treatment of Community-Acquired Pneumonia: A Focus on Lefamulin
por: Eraikhuemen, Nathaniel, et al.
Publicado: (2021)

Efficacy and Safety of Intravenous-to-oral Lefamulin, a Pleuromutilin Antibiotic, for the Treatment of Community-acquired Bacterial Pneumonia: The Phase III Lefamulin Evaluation Against Pneumonia (LEAP 1) Trial
por: File, Thomas M, et al.
Publicado: (2019)

Erratum to: Efficacy and Safety of Intravenous-to-oral Lefamulin, a Pleuromutilin Antibiotic, for the Treatment of Community-acquired Bacterial Pneumonia: The Phase III Lefamulin Evaluation Against Pneumonia (LEAP 1) Trial
por: File, Thomas M, et al.
Publicado: (2020)

LB6. Oral Lefamulin Is Safe and Effective in the Treatment of Adults With Community-Acquired Bacterial Pneumonia (CABP): Results of Lefamulin Evaluation Against Pneumonia (LEAP 2) Study
por: Alexander, Elizabeth, et al.
Publicado: (2018)

2386. Efficacy of Lefamulin (LEF) vs. Moxifloxacin (MOX) Against Common Pathogens in Adults With Community-Acquired Bacterial Pneumonia (CABP): Results From the Phase 3 Lefamulin Evaluation Against Pneumonia (LEAP 1) Study
por: File, Thomas, et al.
Publicado: (2018)

Lefamulin efficacy and safety in a pooled phase 3 clinical trial population with community-acquired bacterial pneumonia and common clinical comorbidities
por: File, Thomas M., et al.
Publicado: (2021)

2233. Efficacy and Symptom Resolution by Visit in Adults With Community-Acquired Bacterial Pneumonia (CABP) Treated With Lefamulin (LEF) or Moxifloxacin (MOX): Pooled Analysis of Lefamulin Evaluation Against Pneumonia (LEAP) 1 and LEAP 2 Study Results
por: Schranz, Jennifer, et al.
Publicado: (2019)

684. Cardiac Safety in Adults with Community-Acquired Bacterial Pneumonia (CABP) Treated with Lefamulin (LEF) or Moxifloxacin (MOX): Analysis of Lefamulin Evaluation Against Pneumonia (LEAP) 1 and LEAP 2 Study Results
por: Darpo, Borje, et al.
Publicado: (2019)

A Red Flag for Community-Acquired Pneumonia in the Elderly
por: Panchabhai, Tanmay S., et al.
Publicado: (2015)

699. Hepatobiliary Safety in Adults With Community-Acquired Bacterial Pneumonia (CABP) Treated With Lefamulin (LEF) or Moxifloxacin (MOX): Pooled Analysis of Lefamulin Evaluation Against Pneumonia (LEAP) 1 and LEAP 2 Study Results
por: Lewis, James H, et al.
Publicado: (2019)

In Vitro Activity of Lefamulin Against a Global Collection of Bacterial Pathogens Commonly Causing Community-Acquired Bacterial Pneumonia (CABP, SENTRY 2015)
por: Paukner, Susanne, et al.
Publicado: (2017)

663. Efficacy and Safety of Lefamulin (LEF) vs. Moxifloxacin (MOX) for Legionella pneumophila (LP) in Patients with Community-Acquired Bacterial Pneumonia (CABP): Pooled Results From the Lefamulin Evaluation Against Pneumonia (LEAP) 1 and LEAP 2 Phase 3 Clinical Trials
por: Shorr, Andrew F, et al.
Publicado: (2019)

Pharmacokinetic/pharmacodynamic target attainment analyses to support intravenous and oral lefamulin dose selection for the treatment of patients with community-acquired bacterial pneumonia
por: Bhavnani, Sujata M, et al.
Publicado: (2019)

Lefamulin in Patients with Community-Acquired Bacterial Pneumonia Caused by Atypical Respiratory Pathogens: Pooled Results from Two Phase 3 Trials
por: Paukner, Susanne, et al.
Publicado: (2021)

Clinical efficacy and safety of favipiravir in the treatment of COVID-19 patients
por: Chen, Ping-Jen, et al.
Publicado: (2021)

717. Lefamulin (LEF) vs. Moxifloxacin (MOX) in Patients With Community-Acquired Bacterial Pneumonia (CABP) at Risk for Poor Efficacy or Safety Outcomes: Pooled Subgroup Analyses From the Lefamulin Evaluation Against Pneumonia (LEAP) 1 and LEAP 2 Phase 3 Noninferiority Clinical Trials
por: Schranz, Jennifer, et al.
Publicado: (2019)

2245. Oral 5-Day Lefamulin for Outpatient Management of Pneumonia Outcomes Research Team (PORT) Risk Class III/IV Community-Acquired Bacterial Pneumonia (CABP): Post Hoc Analysis of the Lefamulin Evaluation Against Pneumonia (LEAP) 2 Phase 3 Study
por: Schranz, Jennifer, et al.
Publicado: (2019)

1353. In Vitro Activity of Lefamulin (LEF) Against Bacterial Pathogens Commonly Causing Community-Acquired Bacterial Pneumonia (CABP): 2016 SENTRY Data From the United States
por: Paukner, Susanne, et al.
Publicado: (2018)

Devastating Community-Acquired Bacterial Meningitis Caused by Hypervirulent Klebsiella pneumoniae in an Immunocompetent Patient
por: Oh, Hyunjoo, et al.
Publicado: (2021)

Decline in invasive pneumococcal disease during COVID-19 pandemic in Taiwan
por: Juan, Hui-Chun, et al.
Publicado: (2021)

Clinicomicrobiological study of community-acquired pneumonia
por: Prasad, Prashasti, et al.
Publicado: (2017)

Omadacycline Pharmacokinetics: Influence of Mortality Risk Score among Patients with Community-Acquired Bacterial Pneumonia
por: Trang, M., et al.
Publicado: (2022)

703. In Vitro Activity of Lefamulin Against Bacterial Pathogens Causing Community-Acquired Bacterial Pneumonia (CABP): SENTRY Surveillance 2017–2018 Results From the United States (US)
por: Sader, Helio S, et al.
Publicado: (2019)

Introduction: lefamulin and pharmacokinetic/pharmacodynamic rationale to support the dose selection of lefamulin
por: Rodvold, Keith A
Publicado: (2019)

In Vitro Activity of Lefamulin against S. aureus Collected Worldwide from Hospitalized Patients with Bacterial Pneumonia
por: Paukner, Susanne, et al.
Publicado: (2017)

Community Acquired Pneumonia CME Infectious Diseases – II
por: Jolobe, O M P
Publicado: (1998)

The efficacy and safety of nemonoxacin compared with levofloxacin in the treatment of community-acquired pneumonia: a systemic review and meta-analysis of randomized controlled trials
por: Chang, Shen-Peng, et al.
Publicado: (2019)

Is it really a study of community-acquired bacterial infections?
por: Chandravanshi, Shivcharan L
Publicado: (2012)

The clinical efficacy of cefoperazone-sulbactam versus piperacillin-tazobactam in the treatment of severe community-acquired pneumonia
por: Lai, Chih-Cheng, et al.
Publicado: (2023)

Clinical Utility of Lefamulin: If Not Now, When?
por: Mercuro, Nicholas J., et al.
Publicado: (2020)

Absence of legionellosis in patients with community-acquired pneumonia requiring hospitalization
por: Kühne, Juliana, et al.
Publicado: (2014)

1365. In Vitro Activity of Lefamulin (LEF) Against Bacterial Pathogens Causing Community-Acquired Bacterial Pneumonia (CABP): SENTRY Surveillance 2016 Results From Asia-Pacific (APAC) and Latin America (LA)
por: Paukner, Susanne, et al.
Publicado: (2018)

Efficacy and Safety of Ceftaroline for the Treatment of Community-Acquired Pneumonia: A Systemic Review and Meta-Analysis of Randomized Controlled Trials
por: Lan, Shao-Huan, et al.
Publicado: (2019)

Novel Human Enterovirus C Infection in Child with Community-acquired Pneumonia
por: Daleno, Cristina, et al.
Publicado: (2012)

Factors influencing severe community-acquired pneumonia few points to ponder
por: Pius, AK Aswin, et al.
Publicado: (2018)

Apoptosis inhibitor of macrophage differentiates bacteria from influenza or COVID-19 in hospitalized adults with community-acquired pneumonia
por: Lai, Xiaofei, et al.
Publicado: (2022)

The association between corticosteroid uses and mortality among severe COVID-19 patients
por: Tang, Hung-Jen, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_eg7d6p9d8qcsjm48d630o7b89d